In Orthopedics, Consolidation's Aftershocks
Executive Summary
Following significant consolidation in 1998, orthopedic industry executives are bracing for more deal-making. A handful of deals in 1999 suggest continued consolidation, but the modesty of the deals also implies that consolidation is unlikely at such an aggressive pace.
You may also be interested in...
J&J Strikes Again in Spine
J&J's aggressive moves in orthopedics has industry executives nervous, most recently about its purchases of artificial disk maker Waldemar Link and biomaterials expert Orquest. The Link valuation (J&J is paying $325 million upfront, plus earn-outs) isn't quite as high as some earlier orthopedics deals, but it is still comparatively substantial. With Link and Orquest under its roof, J&J is poised to assume market leadership in the traditional orthopedics markets and also in spine.
In Orthopedics, Playing From Strength
At an otherwise quiet American Academy of Orthopedic Surgeons meeting, the biggest news was Smith & Nephew's acquisition of pain specialist Oratec Interventions. Times have never been better in orthopedics, and the Smith & Nephew deal raises the question whether the industry is about to see a period of robust deal-making.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.